The Medicines Company Surges on Positive Drug Trial Results

The Medicines Company (NASDAQ: MDCO) announced last week that recent trial data showed positive results for its flagship cholesterol drug, inclisiran. Shares of the company, which has a $3.82 billion market cap, shot up 9.3% in response to the news, and although the stock has given back most of those gains since then, it's still a very encouraging piece of news for the biotech company.